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Abstract The MDM2 oncoprotein is overexpressed in many
human tumors and cancers. MDM2 functions as an E3 ligase
for p53 and for itself. MDM2 also interacts with the retinoblas-
toma protein (RB) and the transcription factor E2F1 to promote
cell cycle S-phase entry. Here, we report that MDM2 protein
expression is cell cycle-regulated, which is dependent on its
RING ¢nger domain and requires Lys446. We show that
MDM2 protein is stabilized at S phase. In addition, overexpres-
sion of MDM2 results in stimulation of E2F activity and accu-
mulation of cells in S phase. These data suggest that ubiquiti-
nation of MDM2 is cell cycle-regulated and that MDM2 may
play a role in cell cycle progression.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The Mdm2 gene was ¢rst identi¢ed as an ampli¢ed gene in
a spontaneously transformed mouse 3T3 cell line. Overexpres-
sion of mdm2 promotes tumorigenesis of NIH3T3 and Rat2
cells [1] and leads to transformation of primary rodent ¢bro-
blasts in cooperation with ras [2]. Importantly, overexpression
of MDM2 has been observed in a variety of human tumors/
cancers, including approximately 30% of human sarcomas [3].
It has been well documented that MDM2 (murine double
minute-2) functions as E3 ligase for p53 and for itself through
its RING ¢nger domain at the C-terminus [4^6]. MDM2
binds to p53 and targets p53 protein degradation via the
ubiquitin-mediated pathway [4,7,8]. MDM2 can also directly
inhibit p53-mediated transactivation [9,10]. On the other
hand, p53 can directly activate MDM2 transcription [11]. In
addition to the critical function on p53, MDM2 has been
shown to interact with a group of cell cycle-related proteins,
including the retinoblastoma protein (RB) and the transcrip-
tion factor E2F1, to promote cell cycle G1^S transition [12^
14].
A body of evidence indicates that MDM2 oncogenic func-
tion is associated with its ability in promoting cell cycle pro-
gression, in particular the S-phase entry. MDM2 inhibits the
growth suppression at G1 imposed by p53 and RB [10,12].
Overproduction of MDM2 can overcome the TGF-L-imposed
growth inhibition via the RB^E2F pathway [15]. Transgenic
mice with targeted MDM2 expression in the mammary glands
exhibit abnormal mammary gland development, high inci-
dence of mammary tumors, and uncoupled S phase from mi-
tosis and polyploidy in cells [16,17].
MDM2 protein has been shown to be phosphorylated at
multiple sites in vivo [18] by ataxia telangiectasia-mutated ki-
nase [19], DNA-dependent protein kinase [20], casein kinase 2
[21], or cyclin A-associated kinase [22]. Interestingly, MDM2
phosphorylation mediated by cyclin A-dependent kinase leads
to reduced interaction between MDM2 and p53 [22]. Given
that cyclin A-associated kinase is critical in promoting cell
cycle progression, it is possible that the cell cycle-dependent
phosphorylation can modulate MDM2 function and that
MDM2 may in turn regulate cell cycle progression.
In this study, we show that MDM2 protein levels are cell
cycle-regulated, which requires the intact RING ¢gure do-
main and Lys446. In addition, our data show that MDM2
protein is accumulated in the S phase, which may play a role
in cell cycle progression.
2. Materials and methods
2.1. Cell culture, synchronization and £uorescence-activated cell sorter
(FACS) analysis
HeLa cells and U2-OS cells were grown in Dulbecco’s modi¢ed
Eagle’s medium containing 10% fetal bovine serum. Cells were
synchronized by double thymidine block and release. Brie£y, cells
were treated with thymidine (2 mM) for 16 h. Cells were then washed
three times, replaced with fresh medium and grown for 8 h prior to a
second treatment with thymidine (2 mM). 16 h after the second thy-
midine treatment, cells were washed, refed with fresh medium, and
collected at the indicated time points. For prometaphase arrest and
release, cells were treated with nocodazole (100 ng/ml) for 16 h. Cells
were washed, refed with fresh medium and collected at the indicated
time. 1U106 cells were stained with propidium iodine and subjected to
FACS analysis and data were analyzed using the Cell Quest program.
2.2. Western blot and Northern blot analyses
Cells were lysed in lysis bu¡er (50 mM Tris^HCl pH 8.0, 125 mM
NaCl, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl £uoride, 2 Wg/
ml leupeptin and 2 Wg/ml aprotinin). Equal amounts of total protein
were subjected to electrophoresis on a 10% sodium dodecyl sulfate
(SDS)^polyacrylamide gel and subjected to Western blot analyses.
Antibodies used were speci¢c for MDM2 (SMP-14; Santa Cruz Bio-
technology or a mixture of monoclonal antibodies 2A10, 4B1, and
3F3, gifts of Dr. J. Chen), cyclin B1 (GNS-1; Pharmingen), L-galac-
tosidase (Promega), c-Myc (9E10, Santa Cruz Biotechnology), CD19
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(Pharmingen) and actin (C-11, Santa Cruz Biotechnology). To deter-
mine the mRNA levels, total RNA was isolated using the TRIZOL0
Reagent (Gibco BRL) according to the manufacturer’s instructions.
5 Wg of total RNA was fractionated on a formaldehyde denaturing gel
and subjected to Northern blot analysis, using a 32P-labeled human
MDM2 cDNA probe. The membrane was rehybridized to a 32P-la-
beled L-actin cDNA probe.
2.3. Transfection, cycloheximide treatment and cell cycle analysis
MDM2 mutants, MDM2C464A and MDM2K446A, were gener-
ated by site-directed mutagenesis according to the manufacturer’s in-
structions (Stratagene) and con¢rmed by DAN sequencing. For ex-
periments to examine ectopic protein expression, cells were transfected
with pCMV-MDM2 plasmid DNA, and with pCMV-L-Gal where
indicated, using FuGENE1 Transfection Reagent (Roch Molecular
Fig. 1. Cell cycle-dependent regulation of MDM2 protein levels. A: HeLa cells were synchronized by double thymidine block and release, and
collected at the indicated time. Cell cycle distribution was analyzed by FACS analysis and the percentage of cells in G1, S and G2/M is pre-
sented. B: Equal amounts of total proteins from synchronized HeLa cells were separated on 10% SDS^PAGE and subjected to Western blot
analysis for MDM2, cyclin B1, and actin. MDM2 and cyclin B1 protein levels were normalized to the actin protein at each corresponding time
point during the cell cycle. The relative intensity is presented, whereas the intensity of the MDM2 and cyclin B1 protein levels from asynchron-
ized cells was arbitrarily set as 1.0. C: U2-OS cells were synchronized by double thymidine block and release, and collected at the indicated
time. Cell cycle distribution was analyzed by FACS analysis and the percentage of cells in G1, S and G2/M is presented. Equal amounts of to-
tal proteins from synchronized U2-OS cells were separated on 10% SDS^PAGE and subjected to Western blot analysis. D: HeLa and U2-OS
cells were synchronized by nocodazole treatment and release, and collected at the indicated time. Cells were subjected to FACS analysis and
Western blot analysis for MDM2, cyclin B1 and actin. The percentage of cells in G1, S and G2/M is shown. E: MDM2 mRNA levels are com-
parable during the cell cycle. HeLa and U2-OS cells were synchronized by double thymidine block and release. Total RNA was isolated and
subjected to Northern blot analysis for MDM2 and L-actin. The intensity of individual MDM2 mRNA and L-actin mRNA bands was quanti-
tated by densitometry scanning. The ratio of MDM2 mRNA over L-actin mRNA at each time point is presented as relative intensity.
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Biochemicals). 6 h after transfection, cells were trypsinized and re-
seeded for an additional 4 h prior to the treatment with double thy-
midine block (2 mM) and release. For cycloheximide treatment, cells
synchronized by double thymidine block and release were treated by
cycloheximide (25 Wg/ml) for the indicated time. Cells were collected
and subjected to FACS and Western blot analyses. To examine the
e¡ect on cell cycle by ectopic expression of MDM2 protein, U2-OS
cells were co-transfected with pCMV-CD19 and pCMV-MDM2 de-
rivative or vector DNA. 48 h after transfection, cells were collected,
stained with a monoclonal antibody speci¢c for CD19 followed by
propidium iodine staining and FACS analysis. The cell cycle distribu-
tion of CD19þ cells was analyzed by Cell Quest program.
3. Results
3.1. Cell cycle-dependent regulation of MDM2 protein
expression
HeLa cells were synchronized at early S phase by double
thymidine block as previously described [23,24] (Fig. 1A).
After release from the double thymidine block, cells entered
S phase at 2^4 h, G2/M phase at 6^8 h and exited M phase
after 10 h (Fig. 1A). As expected, cyclin B1 protein levels
increased in S phase and peaked at G2/M and began to de-
cline at the onset of anaphase (Fig. 1B), via the APC-depen-
dent degradation pathway [25,26]. Similarly, MDM2 protein
appeared to be accumulated when cells entered S phase and
remained at high levels through S and G2/M and declined
thereafter (Fig. 1B). A similar pattern of MDM2 protein ex-
pression was observed in another human cancer cell line, U2-
OS (Fig. 1C).
We then examined whether the decrease in MDM2 protein
levels in M phase correlates with that of cyclin B1. We treated
HeLa and U2-OS cells with nocodazole, which arrests cells at
prometaphase [27]. After release from nocodazole treatment,
cells proceeded through M phase and anaphase in a synchro-
nized fashion (Fig. 1D). Whereas cyclin B1 protein levels were
high in nocodazole-arrested cells and started to decrease at
30^60 min after release, as expected (Fig. 1D), MDM2 protein
levels were down-regulated in nocodazole-arrested cells and
recovered after several hours release from nocodazole treat-
ment. These data suggest that down-regulation of MDM2
protein at M phase proceeds before cyclin B1 degradation.
Since MDM2 protein levels are up-regulated during S-G2
phase, we next examined whether the increased MDM2 pro-
tein level is due to increased MDM2 gene transcription. We
therefore examined the steady-state levels of MDM2 mRNA
during the cell cycle. As shown by Northern blot analysis, the
steady-state levels of MDM2 mRNA appeared to be compa-
rable during the cell cycle in both HeLa and U2-OS cells (Fig.
1E), suggesting that the cell cycle regulation of MDM2 pro-
tein expression is unlikely to be at the transcriptional level,
nor at the mRNA stability level. Rather, the MDM2 protein
stability could be regulated during the cell cycle.
3.2. The RING ¢nger domain of MDM2 is required for cell
cycle-dependent regulation of MDM2 protein
Since the RING ¢nger domain of MDM2 has been shown
to be important for the E3 ligase activity as well as for its self-
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Fig. 2. The RING ¢nger domain of MDM2 is required for cell cycle-dependent regulation. A: HeLa cells were transfected with pCMV-
MDM2, pCMV-MDM2(1^444), pCMV-MDM2C464A or pCMV-MDM2K446A. 6 h after transfection, cells were trypsinized and reseeded for 4 h.
Cells were then synchronized by double thymidine block and release. Equal amounts of total proteins were separated on 10% SDS^PAGE and
subjected to Western blot analysis for MDM2 or actin. B: MDM2 protein is stabilized at S phase. U2-OS cells were transfected with pCMV-
L-Gal and pCMV-MDM2 or pCMV-MDM2(1^444). 6 h after transfection, cells were synchronized by double thymidine block and were then
treated with cycloheximide (CHX) at either 4 h or 12 h after release of thymidine treatment. Cells were collected at the indicated time points.
Aliquots of cells were subjected to FACS analysis, whereas equal amounts of total proteins derived from the cell lysates were separated on
10% SDS^PAGE and subjected to Western blot analysis for MDM2, L-galactosidase and C-Myc.
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ubiquitination [4^6], we reasoned that the E3 ligase activity of
MDM2 may play a role in the cell cycle-dependent regulation
of MDM2 protein levels. We therefore examined the ectopic
expression of MDM2 and its mutant MDM2(1^444), which
lacks the RING ¢nger domain and E3 ligase function, in
synchronized HeLa cells. Cells transfected with either
pCMV-MDM2 or pCMV-MDM2(1^444) were synchronized
by double thymidine block and release. Western blot analysis
showed that the levels of ectopically expressed wild-type
MDM2 protein were high in thymidine-treated cells and re-
mained high in S and G2/M phases, but signi¢cantly declined
thereafter (Fig. 2A). However, the expression level of
MDM2(1^444) was comparable throughout the cell cycle,
suggesting that the RING ¢nger domain plays a critical role
in the cell cycle-dependent regulation of MDM2 protein
stability. To address whether the E3 ligase activity of
MDM2 is involved in cell cycle-dependent regulation on its
protein, we examined the point mutant MDM2 protein, either
defective in E3 ligase (MDM2C464A) [4^6] or defective in auto-
ubiquitination (MDM2K446A) [28,29]. Interestingly, the mu-
tant MDM2C464A protein was still subjected to cell cycle-de-
pendent regulation. In contrast, the mutant MDM2K446Apro-
tein, devoid of auto-ubiquitination, appeared stable through-
out the cell cycle (Fig. 2A). To further investigate the ob-
served cell cycle e¡ect on MDM2 protein expression, we ex-
amined the MDM2 protein half-life in S and G2/M phases.
U2-OS cells were co-transfected with pCMV-L-gal and either
pCMV-MDM2 or pCMV-MDM2(1^444) prior to synchroni-
zation by double thymidine block. At 4 h (S phase) or 12 h
(G2/M phase) after release from the thymidine block, cyclo-
heximide was added to the cells to block protein synthesis. As
shown in Fig. 2C, the wild-type MDM2 protein was stable at
S phase (t1=2s 90 min) (data not shown), whereas the protein
half-life was signi¢cantly shorter at M phase (t1=26 45 min).
In contrast, unlike wild-type MDM2, MDM2(1^444) was sta-
ble in both S and G2/M phases (t1=2s 90 min). As a control,
the protein half-life of the co-expressed L-galactosidase re-
mained comparable in both S and G2/M phases. Further-
more, the half-life of c-Myc protein (approximately 30 min)
was similar in both S phase and M phase, in agreement with
the published data [30^33]. These results indicate that the cell
cycle-dependent regulation of MDM2 is likely through the
ubiquitin-mediated proteasome degradation pathway and the
C-terminal RING ¢nger domain plays a critical role in this
process.
3.3. Overexpression of MDM2 leads to stimulation of E2F
activity and an increase in S-phase cell population
Given that MDM2 protein level is increased in S phase
during the cell cycle, we reasoned that MDM2 may modulate
the RB^E2F pathway in promoting the cell cycle S-phase en-
try [12,13]. Indeed, as shown in Fig. 3A, ectopic expression of
wild-type MDM2 led to a clear stimulation of the E2F activ-
ity. Importantly, mutant MDM2(1^444) lacking the RING
¢nger domain exhibited even higher activity in stimulating
E2F activity (Fig. 3A), likely due to the stabilization of the
mutant MDM2 protein. Furthermore, ectopic expression of
MDM2 in U2-OS cells led to a clear increase in S-phase cell
population (Fig. 3B). Taken together, these data suggest that
the up-regulation of MDM2 protein at S phase may be im-
portant in modulation of the RB^E2F pathway in promoting
cell cycle S-phase entry.
4. Discussion
Our data indicate that MDM2 protein is stabilized at
S phase and declined at G2/M phases, suggesting that MDM2
protein degradation is regulated during the cell cycle. Interest-
ingly, the degradation of MDM2 protein requires the RING
¢nger domain but does not require its own E3 ligase activity
since the point mutation inactivating the E3 ligase
(MDM2C464A), which leads to MDM2 protein stabilization,
does not block the cell cycle-dependent degradation. How-
ever, a single amino acid substitution at Lys446, a site iden-
ti¢ed as auto-ubiquitination of MDM2 [28,29], does abolish
the cell cycle-dependent regulation of the MDM2 protein.
Together, these observations imply that E3 ligase activity of
MDM2 is critical for MDM2 protein stability and another
Fig. 3. Overexpression of MDM2 leads to enhanced E2F activity
and increase in S-phase cell population. A: Saos-2 cells were co-
transfected with pCMV-E2F1, pCMV-DP1 and either pCMV-
MDM2, pCMV-MDM2(1^444) or vector DNA in the presence of
pCMV-L-Gal and an E2F reporter (DHFR-luciferase). 24 h after
transfection, cells were collected and lysed in the luciferase lysis
bu¡er. The luciferase activity was normalized to L-galactosidase ac-
tivity and presented as fold activation. Inset: Western blot analysis
data showing the MDM2 protein levels in cells transfected with
wild-type MDM2 (WT), MDM2(1^444) (MDM2v) or vector control
(V). B: U2-OS cells were co-transfected with pCMV-CD19 and
pCMV-MDM2 or vector DNA. 48 h after transfection, cells were
harvested, stained for CD19 and propidium iodide, and subjected to
FACS analysis. A representative of the cell cycle distribution of
CD19þ cells from three experiments is shown.
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E3 ligase, however, is responsible for cell cycle-dependent
MDM2 protein degradation. It is interesting to note that in-
hibition of cdk by roscovitine results in reduced MDM2 pro-
tein levels [34] and that murine mdm2 protein is phosphory-
lated by cyclin A-associated kinase at Thr216, resulting in the
increased ARF^MDM2 interaction [22]. The human MDM2
protein, although lacking the conserved Thr residue at the
corresponding position, contains a cluster of conserved serines
or threonines around this region and therefore may be regu-
lated in a similar fashion. It is possible that speci¢c cell cycle-
dependent phosphorylation may serve as speci¢c signal(s) to
trigger the modulation of MDM2 protein stability. Further
work is needed to elucidate the exact mechanism.
It has been well established that MDM2 oncogenic function
is associated with its ability in promoting cell cycle progres-
sion and/or inhibit apoptosis. MDM2 inhibits RB and acti-
vates E2F activity [12,13]. Our data from this study also in-
dicate that activation of E2F correlates well with the amount
of MDM2 protein. Furthermore, overproduction of MDM2
can promote S-phase entry. These data suggest that MDM2
may play an important role in cell cycle progression.
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